Trial Profile
An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcutaneous Gamunex® 10% (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) in Subjects With Primary Immunodeficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Pharmacokinetics
- Sponsors Grifols
- 01 Mar 2022 Results of pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing by using data from three studies including this study published in the International Immunopharmacology
- 18 Sep 2014 New trial record